Can Lisinopril Cause Cough?

How Common Is Lisinopril-Induced Cough?

ACE inhibitor cough is one of the most frequently reported adverse drug reactions in cardiovascular medicine, and lisinopril is the most prescribed ACE inhibitor in the United States with over 80 million dispensed prescriptions annually. The reported incidence ranges from about 5% in clinical trials to 15% or higher in post-marketing surveillance and community-based studies [1].

Women develop the cough roughly twice as often as men. A meta-analysis published in the Annals of Internal Medicine found a pooled incidence of 9.9% across ACE inhibitor classes, with no statistically significant difference between individual agents like lisinopril, enalapril, or ramipril [2]. Ethnicity matters too. Studies in East Asian populations report cough rates between 15% and 25%, likely related to genetic polymorphisms in the bradykinin B2 receptor and ACE gene [3]. Black patients also appear to experience ACE inhibitor cough at slightly higher rates than white patients, though the data are less consistent.

The cough is the single most common reason patients discontinue ACE inhibitor therapy. A real-world analysis of UK primary care records found that 12.4% of patients starting an ACE inhibitor switched to an ARB within the first year, with cough cited as the leading cause [4]. That represents a significant clinical problem because untreated or undertreated hypertension carries its own risks.

Why Does Lisinopril Cause Cough? The Bradykinin Mechanism

Lisinopril lowers blood pressure by blocking angiotensin-converting enzyme, which prevents the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. That same enzyme also degrades bradykinin, a peptide that dilates blood vessels and lowers blood pressure through a separate pathway.

When ACE is inhibited, bradykinin accumulates. Bradykinin itself is not the direct irritant. It sensitizes airway sensory nerve fibers (C-fibers) and stimulates the release of substance P and prostaglandins in the bronchial mucosa [5]. These mediators trigger the cough reflex by lowering the threshold for activation of the vagal afferent nerves in the upper and lower airways. Think of it as the cough switch being turned to a more sensitive setting.

This mechanism explains several clinical observations. The cough is always dry because there is no mucus hypersecretion or bronchial inflammation. It tends to worsen at night or when lying down because postural changes increase vagal tone. And it is a class effect: switching from lisinopril to another ACE inhibitor like enalapril or benazepril will not fix the problem in most patients [6].

A 2014 pharmacogenomics study in Clinical Pharmacology & Therapeutics identified that carriers of the BDKRB2 receptor variant rs1799722 (T/T genotype) had a 2.6-fold higher odds of developing ACE inhibitor cough compared to C/C carriers [7]. This finding supports the bradykinin hypothesis and may eventually allow clinicians to predict who will develop this side effect before prescribing.

When Does the Cough Start, and How Long Does It Last?

The onset window is wide. Most patients notice the cough within one to six months of starting lisinopril, but it can appear as early as the first week or as late as several years into treatment [1]. This delayed onset often causes confusion. Patients who have taken lisinopril for two years without problems may not connect a new cough to a medication they have been tolerating.

The cough itself is described as a persistent, dry, tickling sensation in the back of the throat. It does not produce sputum. Patients frequently describe it as an "annoying" or "nagging" cough that interrupts sleep and conversation. Some report a scratchy or "peppery" throat sensation preceding each coughing episode.

After discontinuation, the cough resolves in the majority of patients within one to four weeks [8]. A smaller subset, perhaps 10% to 15% of those affected, reports persistent cough for up to three months after stopping the drug. Dr. William B. White, professor of medicine at the University of Connecticut, has stated: "The hallmark of ACE inhibitor cough is resolution after drug withdrawal. If the cough persists beyond 8 weeks after stopping, the clinician should look for other causes."

Ruling Out Other Causes: Is It Really the Lisinopril?

Before attributing a cough to lisinopril, other common causes need to be excluded. Cough is one of the most frequent symptoms in primary care, and many conditions can mimic ACE inhibitor cough.

Gastroesophageal reflux disease (GERD) causes chronic cough in up to 40% of patients with unexplained cough, and ACE inhibitors can worsen reflux by relaxing the lower esophageal sphincter [9]. Postnasal drip from allergic or nonallergic rhinitis is another frequent culprit. Asthma, particularly the cough-variant form, should also be considered, especially in patients with a history of atopy or wheezing.

A practical diagnostic approach recommended by the American College of Chest Physicians (ACCP) is the "therapeutic withdrawal trial" [10]. Stop the ACE inhibitor, switch to an ARB or another antihypertensive class, and observe for four weeks. If the cough resolves, the diagnosis is confirmed. If it persists, further workup for GERD, upper airway cough syndrome, or asthma is warranted.

Key distinguishing features of ACE inhibitor cough include:

• No associated fever, sputum production, or weight loss
• No seasonal or environmental pattern
• Temporal relationship with starting or dose-increasing the ACE inhibitor
• Absence of wheezing on auscultation
• Normal chest radiograph

Heart failure should also be considered. Lisinopril is commonly prescribed for heart failure, and pulmonary congestion from decompensated heart failure can itself cause cough. A BNP level and chest X-ray can help differentiate the two.

Treatment Options: What to Do If Lisinopril Is Causing Your Cough

The most effective treatment is switching to an ARB. ARBs block the angiotensin II receptor directly without affecting bradykinin metabolism, so they do not cause the cough [11]. The ONTARGET trial (N=25,620) demonstrated that telmisartan was non-inferior to ramipril for cardiovascular outcomes, while producing significantly lower rates of cough (1.1% vs. 4.2%, P<0.001) [12]. This trial and others have made ARBs the accepted first-line alternative for patients who develop ACE inhibitor cough.

Common ARB substitutions include:

• Losartan 25 to 100 mg daily (the most frequently prescribed switch)
• Valsartan 80 to 320 mg daily
• Irbesartan 150 to 300 mg daily
• Telmisartan 40 to 80 mg daily
• Olmesartan 20 to 40 mg daily

The 2017 ACC/AHA Hypertension Guideline explicitly lists ARBs as a recommended alternative for patients intolerant of ACE inhibitors due to cough [13]. The guideline treats the two classes as interchangeable for most indications, including hypertension, heart failure with reduced ejection fraction, diabetic nephropathy, and post-myocardial infarction care.

For patients who want to try to continue lisinopril despite the cough, a few pharmacologic remedies have been studied with mixed results. Sodium cromoglycate inhaler (an old mast-cell stabilizer) reduced ACE inhibitor cough in a small crossover trial [14]. Iron supplementation has shown modest benefit in one pilot study, based on the hypothesis that iron depletion increases substance P sensitivity. Neither approach is standard practice, and the evidence is not strong enough to recommend them over switching drug classes.

Dose reduction occasionally helps but usually does not eliminate the cough entirely. The bradykinin effect appears to be relatively dose-independent once a threshold level of ACE inhibition is reached.

Special Populations: Who Is at Higher Risk?

Women are the highest-risk group. A large Danish cohort study (N=53,163) found that women had a 1.8-fold higher adjusted risk of developing ACE inhibitor cough compared to men (HR 1.82 to 95% CI 1.66 to 1.99) [15]. Hormonal factors may play a role, as estrogen upregulates bradykinin receptor expression in airway tissue.

Patients of East Asian descent face the highest absolute risk. Japanese and Chinese population studies consistently report cough rates of 15% to 25% with ACE inhibitors [3]. The 2019 Japanese Society of Hypertension guidelines recommend ARBs as first-line therapy partly for this reason, diverging from Western guidelines that treat ACE inhibitors and ARBs as equivalent first choices [16].

Patients with a history of allergic conditions, asthma, or bronchial hyperreactivity may be more susceptible, though the data are inconsistent. Prior ACE inhibitor cough with any agent in the class is the strongest predictor: recurrence rates exceed 80% when switching between ACE inhibitors [6].

Older adults may under-report the cough or attribute it to aging, postnasal drip, or seasonal allergies. Clinicians prescribing lisinopril to patients over 65 should specifically ask about new cough at follow-up visits.

ACE Inhibitor Cough vs. Angioedema: Knowing the Difference

Angioedema is the serious, potentially life-threatening cousin of ACE inhibitor cough. Both are mediated by bradykinin accumulation, but angioedema involves swelling of deeper tissue layers, typically in the lips, tongue, face, or throat [17].

ACE inhibitor angioedema occurs in approximately 0.1% to 0.7% of users, with Black patients at three- to four-fold higher risk compared to white patients [18]. The OCTAVE trial (N=25,302) found an angioedema rate of 0.68% with enalapril vs. 0.12% with the ARB omapatrilat (withdrawn for this reason), confirming the bradykinin link [19].

Dr. Nancy J. Brown, then professor of pharmacology at Vanderbilt University, noted in a review published in Circulation: "Patients who develop ACE inhibitor cough are not at increased risk of angioedema, but both reactions share the bradykinin pathway. Any patient presenting with facial or oropharyngeal swelling on an ACE inhibitor should have the drug permanently discontinued."

Red flags that distinguish angioedema from simple cough:

• Swelling of the lips, tongue, face, or uvula
• Difficulty breathing or swallowing
• Voice changes or hoarseness
• Abdominal pain (intestinal angioedema, a less common variant)

Angioedema is a medical emergency. Patients should call 911 or go to the nearest emergency department. ACE inhibitors must be permanently stopped, and ARBs should be used with caution in these patients, though the cross-reactivity rate with ARBs for angioedema is low (estimated at 2% to 9%) [20].

Can You Prevent ACE Inhibitor Cough?

No reliable prevention strategy exists. The cough is an idiosyncratic reaction that cannot be predicted with certainty before prescribing. Pharmacogenomic testing for BDKRB2 variants is not yet part of routine clinical practice, though it may become relevant as precision medicine expands [7].

What clinicians can do is counsel patients proactively. At the time of prescribing lisinopril, the patient should be told that a dry cough may develop weeks to months later, that it is a known side effect and not dangerous, and that effective alternatives exist. This framing prevents unnecessary workups for lung disease and reduces patient anxiety.

Some clinicians now prescribe ARBs first-line to avoid the cough issue entirely. The 2018 ESC/ESH Hypertension Guidelines list both ACE inhibitors and ARBs as first-line agents with equivalent recommendation strength (Class I, Level A) [21]. Given that ARBs produce fewer side effects with comparable efficacy, their use as initial therapy is increasing, particularly in populations known to have higher cough rates.

For patients already established on lisinopril with good blood pressure control and no cough, there is no reason to switch. The medication should continue as prescribed. The cough is the indication for change, not a reason for preemptive avoidance in all patients.

Patients who develop cough should contact their prescriber rather than stopping lisinopril abruptly. Uncontrolled hypertension carries short-term risks including hypertensive urgency, and a supervised medication transition ensures continuous blood pressure management.